2019
Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity
Brooks JP, Azmy V, Thompson A, Luon D, Prozora SD, Price C, Hsu FI. Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity. Journal Of Oncology Pharmacy Practice 2019, 26: 228-231. PMID: 30885040, DOI: 10.1177/1078155219836478.Peer-Reviewed Original ResearchConceptsOrthopedic malignanciesHypersensitivity reactionsEtoposide phosphatePediatric patientsEtoposide hypersensitivityLarge academic medical centerAcademic medical centerCase of etoposideContinued therapyChart reviewFurther therapyFirst dosesFull dosesEwing's sarcomaMedical CenterPatientsMalignancySafe alternativeEtoposideHypersensitivityTherapyDiphenhydramineDosesPremedicationSarcoma
2016
Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies
Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI, Hong D, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. The Journal Of Allergy And Clinical Immunology In Practice 2016, 4: 497-504. PMID: 26895621, DOI: 10.1016/j.jaip.2015.12.019.Peer-Reviewed Original ResearchConceptsRapid drug desensitizationDrug desensitizationAllergic patientsLife expectancyMonoclonal antibodiesNonallergic control groupOptimal pharmacological agentsOverall health costsFirst-line therapyAdministration of carboplatinConnective tissue diseaseStandard of careIndividual patient reactionsDesensitized patientsNonallergic groupAllergic groupLine therapyRisk stratificationTissue diseaseHypersensitivity reactionsChronic diseasesOvarian cancerSevere reactionsNonsignificant increasePharmacological agents
2010
Drug Desensitizations in the Management of Allergy and Anaphylaxis to Chemotherapeutic Agents and Monoclonal Antibodies
Banerji A, Brennan P, Hesterberg P, Oren E, Hsu F. Drug Desensitizations in the Management of Allergy and Anaphylaxis to Chemotherapeutic Agents and Monoclonal Antibodies. 2010, 297-311. DOI: 10.1007/978-1-60327-951-2_19.ChaptersDrug hypersensitivity reactionsDrug desensitizationManagement of allergyChemotherapeutic agentsHypersensitivity reactionsMonoclonal antibodiesLife-threatening infectious diseaseDrug-allergic individualsIgE-mediated drug hypersensitivity reactionsMast cell degranulationImmunology specialistsDesensitization protocolRheumatologic diseasesIncremental dosesCautious administrationCell degranulationSensitized individualsInfectious diseasesSmall molecule therapeuticsAllergyDesensitizationNumerous cancersAntibodiesDiseaseDrugs
2008
Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases
Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA. Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases. Journal Of Allergy And Clinical Immunology 2008, 122: 574-580. PMID: 18502492, DOI: 10.1016/j.jaci.2008.02.044.Peer-Reviewed Original ResearchConceptsHypersensitivity reactionsRapid desensitizationLife-threatening hypersensitivity reactionMedical intensive care unitChemotherapeutic drugsRapid desensitization protocolRapid drug desensitizationIntensive care unitStandard of careFirst desensitizationTemporary tolerizationDesensitization protocolDrug desensitizationCare unitDrug allergensPreferred agentOutpatient settingIntraperitoneal routeSubsequent infusionLiposomal doxorubicinAllergic reactionsAlternative drugsInitial desensitizationTarget doseTreatment records